Prevention of hepatitis B recurrence after liver transplantation using lamivudine or lamivudine combined with hepatitis B Immunoglobulin prophylaxis
The aim of our study was to determine the outcomes of liver transplant recipients receiving either lamivudine (LAM) monotherapy or LAM combined with low‐dose intramuscular (IM) hepatitis B Immunoglobulin (HBIG) therapy. We performed a retrospective review of the medical records of patients that had...
Gespeichert in:
| Veröffentlicht in: | Liver transplantation 2006-02, Vol.12 (2), p.253-258 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 258 |
|---|---|
| container_issue | 2 |
| container_start_page | 253 |
| container_title | Liver transplantation |
| container_volume | 12 |
| creator | Zheng, Shusen Chen, Yaomin Liang, Tingbo Lu, Anwei Wang, Weilin Shen, Yan Zhang, Min |
| description | The aim of our study was to determine the outcomes of liver transplant recipients receiving either lamivudine (LAM) monotherapy or LAM combined with low‐dose intramuscular (IM) hepatitis B Immunoglobulin (HBIG) therapy. We performed a retrospective review of the medical records of patients that had had liver transplantation in a single center for HBV‐related liver diseases from December 1999 to June 2004. A total of 165 patients received LAM monotherapy (51 patients) or combined prophylaxis (114 patients) post‐liver transplantation (LT) with a mean follow‐up of 20.13 months. Hepatitis B relapsed in 21 patients of the hepatitis B surface antigen (HBsAg) carriers who received LAM monotherapy, with a 1‐ and 2‐yr actuarial risk of 27.4% and 39.7%. Recurrence occurred in 16 patients of 114 patients receiving the combined prophylaxis, with a 1‐ and 2‐yr recurrence rate of 13.5% and 15.2% (P= 0.024). A total of 25 cases (67.6%) with YMDD mutants were detected in all the 37 patients, 14 cases (66.7%) in the monotherapy group and 11 cases (68.8%) in the combination group. In conclusion, LAM and low‐dose intramuscular HBIG treatment demonstrates a better result than LAM monotherapy, as prophylaxis against post‐LT reinfection of the graft, but the safety and efficacy as a substitution for high‐dose intravenous HBIG with LAM needs to be investigated further. Liver Transpl 12:253–258, 2006. © 2006 AASLD. |
| doi_str_mv | 10.1002/lt.20701 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_902330641</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>902330641</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3851-5afefe09637f4f074457cbbd1296a32499cf43618884fa17fc84a5c19a965f9c3</originalsourceid><addsrcrecordid>eNp9kctu1DAUhi0EoheQeALkFbBJsRNf4iVUUCqN1C7KOnI8xx0jxw62M2XegwfGdEbQLmDjY0vf-Y6PfoReUXJGCWnf-3LWEknoE3RMeSsbwWT39M9d8CN0kvM3QijlijxHR1QwJqnix-jndYIthOJiwNHiDcy6uOIy_ogTmCUlCAawtgUS9m5bz5J0yLPXoej7riW7cIu9ntx2WbsAOKaHLxOnsdY1vnNl88h_OU1LiLc-jot3Ac8pzpud1z9cfoGeWe0zvDzUU_T186eb8y_N6uri8vzDqjFdz2nDtQULRIlOWmaJZIxLM45r2iqhu5YpZSzrBO37nllNpTU909xQpZXgVpnuFL3de-vs7wvkMkwuG_B1OYhLHhRpu44IRiv55r-kkKJ-iYkKvtuDJsWcE9hhTm7SaTdQMvzOavBluM-qoq8PzmWcYP0XPIRTgWYP3DkPu3-KhtXNXvgL2bOgsQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>67638546</pqid></control><display><type>article</type><title>Prevention of hepatitis B recurrence after liver transplantation using lamivudine or lamivudine combined with hepatitis B Immunoglobulin prophylaxis</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><source>Alma/SFX Local Collection</source><creator>Zheng, Shusen ; Chen, Yaomin ; Liang, Tingbo ; Lu, Anwei ; Wang, Weilin ; Shen, Yan ; Zhang, Min</creator><creatorcontrib>Zheng, Shusen ; Chen, Yaomin ; Liang, Tingbo ; Lu, Anwei ; Wang, Weilin ; Shen, Yan ; Zhang, Min</creatorcontrib><description>The aim of our study was to determine the outcomes of liver transplant recipients receiving either lamivudine (LAM) monotherapy or LAM combined with low‐dose intramuscular (IM) hepatitis B Immunoglobulin (HBIG) therapy. We performed a retrospective review of the medical records of patients that had had liver transplantation in a single center for HBV‐related liver diseases from December 1999 to June 2004. A total of 165 patients received LAM monotherapy (51 patients) or combined prophylaxis (114 patients) post‐liver transplantation (LT) with a mean follow‐up of 20.13 months. Hepatitis B relapsed in 21 patients of the hepatitis B surface antigen (HBsAg) carriers who received LAM monotherapy, with a 1‐ and 2‐yr actuarial risk of 27.4% and 39.7%. Recurrence occurred in 16 patients of 114 patients receiving the combined prophylaxis, with a 1‐ and 2‐yr recurrence rate of 13.5% and 15.2% (P= 0.024). A total of 25 cases (67.6%) with YMDD mutants were detected in all the 37 patients, 14 cases (66.7%) in the monotherapy group and 11 cases (68.8%) in the combination group. In conclusion, LAM and low‐dose intramuscular HBIG treatment demonstrates a better result than LAM monotherapy, as prophylaxis against post‐LT reinfection of the graft, but the safety and efficacy as a substitution for high‐dose intravenous HBIG with LAM needs to be investigated further. Liver Transpl 12:253–258, 2006. © 2006 AASLD.</description><identifier>ISSN: 1527-6465</identifier><identifier>EISSN: 1527-6473</identifier><identifier>DOI: 10.1002/lt.20701</identifier><identifier>PMID: 16447195</identifier><language>eng</language><publisher>Hoboken: Wiley Subscription Services, Inc., A Wiley Company</publisher><subject>Adult ; Cohort Studies ; Dose-Response Relationship, Drug ; Drug Administration Schedule ; Drug Therapy, Combination ; Female ; Follow-Up Studies ; Graft Rejection - prevention & control ; Graft Survival ; Hepatitis B surface antigen ; Hepatitis B, Chronic - complications ; Hepatitis B, Chronic - prevention & control ; Humans ; Immunoglobulins ; Immunoglobulins - administration & dosage ; Intravenous administration ; Lamivudine ; Lamivudine - administration & dosage ; Liver diseases ; Liver Failure - etiology ; Liver Failure - mortality ; Liver Failure - surgery ; Liver transplantation ; Liver Transplantation - adverse effects ; Liver Transplantation - methods ; Male ; medical records ; Middle Aged ; Postoperative Complications - prevention & control ; Probability ; Prophylaxis ; Retrospective Studies ; Risk Assessment ; Secondary Prevention ; Statistics, Nonparametric ; Treatment Outcome</subject><ispartof>Liver transplantation, 2006-02, Vol.12 (2), p.253-258</ispartof><rights>Copyright © 2006 American Association for the Study of Liver Diseases</rights><rights>Copyright 2006 AASLD</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3851-5afefe09637f4f074457cbbd1296a32499cf43618884fa17fc84a5c19a965f9c3</citedby><cites>FETCH-LOGICAL-c3851-5afefe09637f4f074457cbbd1296a32499cf43618884fa17fc84a5c19a965f9c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Flt.20701$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Flt.20701$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16447195$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zheng, Shusen</creatorcontrib><creatorcontrib>Chen, Yaomin</creatorcontrib><creatorcontrib>Liang, Tingbo</creatorcontrib><creatorcontrib>Lu, Anwei</creatorcontrib><creatorcontrib>Wang, Weilin</creatorcontrib><creatorcontrib>Shen, Yan</creatorcontrib><creatorcontrib>Zhang, Min</creatorcontrib><title>Prevention of hepatitis B recurrence after liver transplantation using lamivudine or lamivudine combined with hepatitis B Immunoglobulin prophylaxis</title><title>Liver transplantation</title><addtitle>Liver Transpl</addtitle><description>The aim of our study was to determine the outcomes of liver transplant recipients receiving either lamivudine (LAM) monotherapy or LAM combined with low‐dose intramuscular (IM) hepatitis B Immunoglobulin (HBIG) therapy. We performed a retrospective review of the medical records of patients that had had liver transplantation in a single center for HBV‐related liver diseases from December 1999 to June 2004. A total of 165 patients received LAM monotherapy (51 patients) or combined prophylaxis (114 patients) post‐liver transplantation (LT) with a mean follow‐up of 20.13 months. Hepatitis B relapsed in 21 patients of the hepatitis B surface antigen (HBsAg) carriers who received LAM monotherapy, with a 1‐ and 2‐yr actuarial risk of 27.4% and 39.7%. Recurrence occurred in 16 patients of 114 patients receiving the combined prophylaxis, with a 1‐ and 2‐yr recurrence rate of 13.5% and 15.2% (P= 0.024). A total of 25 cases (67.6%) with YMDD mutants were detected in all the 37 patients, 14 cases (66.7%) in the monotherapy group and 11 cases (68.8%) in the combination group. In conclusion, LAM and low‐dose intramuscular HBIG treatment demonstrates a better result than LAM monotherapy, as prophylaxis against post‐LT reinfection of the graft, but the safety and efficacy as a substitution for high‐dose intravenous HBIG with LAM needs to be investigated further. Liver Transpl 12:253–258, 2006. © 2006 AASLD.</description><subject>Adult</subject><subject>Cohort Studies</subject><subject>Dose-Response Relationship, Drug</subject><subject>Drug Administration Schedule</subject><subject>Drug Therapy, Combination</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Graft Rejection - prevention & control</subject><subject>Graft Survival</subject><subject>Hepatitis B surface antigen</subject><subject>Hepatitis B, Chronic - complications</subject><subject>Hepatitis B, Chronic - prevention & control</subject><subject>Humans</subject><subject>Immunoglobulins</subject><subject>Immunoglobulins - administration & dosage</subject><subject>Intravenous administration</subject><subject>Lamivudine</subject><subject>Lamivudine - administration & dosage</subject><subject>Liver diseases</subject><subject>Liver Failure - etiology</subject><subject>Liver Failure - mortality</subject><subject>Liver Failure - surgery</subject><subject>Liver transplantation</subject><subject>Liver Transplantation - adverse effects</subject><subject>Liver Transplantation - methods</subject><subject>Male</subject><subject>medical records</subject><subject>Middle Aged</subject><subject>Postoperative Complications - prevention & control</subject><subject>Probability</subject><subject>Prophylaxis</subject><subject>Retrospective Studies</subject><subject>Risk Assessment</subject><subject>Secondary Prevention</subject><subject>Statistics, Nonparametric</subject><subject>Treatment Outcome</subject><issn>1527-6465</issn><issn>1527-6473</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kctu1DAUhi0EoheQeALkFbBJsRNf4iVUUCqN1C7KOnI8xx0jxw62M2XegwfGdEbQLmDjY0vf-Y6PfoReUXJGCWnf-3LWEknoE3RMeSsbwWT39M9d8CN0kvM3QijlijxHR1QwJqnix-jndYIthOJiwNHiDcy6uOIy_ogTmCUlCAawtgUS9m5bz5J0yLPXoej7riW7cIu9ntx2WbsAOKaHLxOnsdY1vnNl88h_OU1LiLc-jot3Ac8pzpud1z9cfoGeWe0zvDzUU_T186eb8y_N6uri8vzDqjFdz2nDtQULRIlOWmaJZIxLM45r2iqhu5YpZSzrBO37nllNpTU909xQpZXgVpnuFL3de-vs7wvkMkwuG_B1OYhLHhRpu44IRiv55r-kkKJ-iYkKvtuDJsWcE9hhTm7SaTdQMvzOavBluM-qoq8PzmWcYP0XPIRTgWYP3DkPu3-KhtXNXvgL2bOgsQ</recordid><startdate>200602</startdate><enddate>200602</enddate><creator>Zheng, Shusen</creator><creator>Chen, Yaomin</creator><creator>Liang, Tingbo</creator><creator>Lu, Anwei</creator><creator>Wang, Weilin</creator><creator>Shen, Yan</creator><creator>Zhang, Min</creator><general>Wiley Subscription Services, Inc., A Wiley Company</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7T5</scope><scope>7U9</scope><scope>H94</scope></search><sort><creationdate>200602</creationdate><title>Prevention of hepatitis B recurrence after liver transplantation using lamivudine or lamivudine combined with hepatitis B Immunoglobulin prophylaxis</title><author>Zheng, Shusen ; Chen, Yaomin ; Liang, Tingbo ; Lu, Anwei ; Wang, Weilin ; Shen, Yan ; Zhang, Min</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3851-5afefe09637f4f074457cbbd1296a32499cf43618884fa17fc84a5c19a965f9c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Adult</topic><topic>Cohort Studies</topic><topic>Dose-Response Relationship, Drug</topic><topic>Drug Administration Schedule</topic><topic>Drug Therapy, Combination</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Graft Rejection - prevention & control</topic><topic>Graft Survival</topic><topic>Hepatitis B surface antigen</topic><topic>Hepatitis B, Chronic - complications</topic><topic>Hepatitis B, Chronic - prevention & control</topic><topic>Humans</topic><topic>Immunoglobulins</topic><topic>Immunoglobulins - administration & dosage</topic><topic>Intravenous administration</topic><topic>Lamivudine</topic><topic>Lamivudine - administration & dosage</topic><topic>Liver diseases</topic><topic>Liver Failure - etiology</topic><topic>Liver Failure - mortality</topic><topic>Liver Failure - surgery</topic><topic>Liver transplantation</topic><topic>Liver Transplantation - adverse effects</topic><topic>Liver Transplantation - methods</topic><topic>Male</topic><topic>medical records</topic><topic>Middle Aged</topic><topic>Postoperative Complications - prevention & control</topic><topic>Probability</topic><topic>Prophylaxis</topic><topic>Retrospective Studies</topic><topic>Risk Assessment</topic><topic>Secondary Prevention</topic><topic>Statistics, Nonparametric</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zheng, Shusen</creatorcontrib><creatorcontrib>Chen, Yaomin</creatorcontrib><creatorcontrib>Liang, Tingbo</creatorcontrib><creatorcontrib>Lu, Anwei</creatorcontrib><creatorcontrib>Wang, Weilin</creatorcontrib><creatorcontrib>Shen, Yan</creatorcontrib><creatorcontrib>Zhang, Min</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><jtitle>Liver transplantation</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zheng, Shusen</au><au>Chen, Yaomin</au><au>Liang, Tingbo</au><au>Lu, Anwei</au><au>Wang, Weilin</au><au>Shen, Yan</au><au>Zhang, Min</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prevention of hepatitis B recurrence after liver transplantation using lamivudine or lamivudine combined with hepatitis B Immunoglobulin prophylaxis</atitle><jtitle>Liver transplantation</jtitle><addtitle>Liver Transpl</addtitle><date>2006-02</date><risdate>2006</risdate><volume>12</volume><issue>2</issue><spage>253</spage><epage>258</epage><pages>253-258</pages><issn>1527-6465</issn><eissn>1527-6473</eissn><abstract>The aim of our study was to determine the outcomes of liver transplant recipients receiving either lamivudine (LAM) monotherapy or LAM combined with low‐dose intramuscular (IM) hepatitis B Immunoglobulin (HBIG) therapy. We performed a retrospective review of the medical records of patients that had had liver transplantation in a single center for HBV‐related liver diseases from December 1999 to June 2004. A total of 165 patients received LAM monotherapy (51 patients) or combined prophylaxis (114 patients) post‐liver transplantation (LT) with a mean follow‐up of 20.13 months. Hepatitis B relapsed in 21 patients of the hepatitis B surface antigen (HBsAg) carriers who received LAM monotherapy, with a 1‐ and 2‐yr actuarial risk of 27.4% and 39.7%. Recurrence occurred in 16 patients of 114 patients receiving the combined prophylaxis, with a 1‐ and 2‐yr recurrence rate of 13.5% and 15.2% (P= 0.024). A total of 25 cases (67.6%) with YMDD mutants were detected in all the 37 patients, 14 cases (66.7%) in the monotherapy group and 11 cases (68.8%) in the combination group. In conclusion, LAM and low‐dose intramuscular HBIG treatment demonstrates a better result than LAM monotherapy, as prophylaxis against post‐LT reinfection of the graft, but the safety and efficacy as a substitution for high‐dose intravenous HBIG with LAM needs to be investigated further. Liver Transpl 12:253–258, 2006. © 2006 AASLD.</abstract><cop>Hoboken</cop><pub>Wiley Subscription Services, Inc., A Wiley Company</pub><pmid>16447195</pmid><doi>10.1002/lt.20701</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1527-6465 |
| ispartof | Liver transplantation, 2006-02, Vol.12 (2), p.253-258 |
| issn | 1527-6465 1527-6473 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_902330641 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete; Alma/SFX Local Collection |
| subjects | Adult Cohort Studies Dose-Response Relationship, Drug Drug Administration Schedule Drug Therapy, Combination Female Follow-Up Studies Graft Rejection - prevention & control Graft Survival Hepatitis B surface antigen Hepatitis B, Chronic - complications Hepatitis B, Chronic - prevention & control Humans Immunoglobulins Immunoglobulins - administration & dosage Intravenous administration Lamivudine Lamivudine - administration & dosage Liver diseases Liver Failure - etiology Liver Failure - mortality Liver Failure - surgery Liver transplantation Liver Transplantation - adverse effects Liver Transplantation - methods Male medical records Middle Aged Postoperative Complications - prevention & control Probability Prophylaxis Retrospective Studies Risk Assessment Secondary Prevention Statistics, Nonparametric Treatment Outcome |
| title | Prevention of hepatitis B recurrence after liver transplantation using lamivudine or lamivudine combined with hepatitis B Immunoglobulin prophylaxis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-04T07%3A03%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prevention%20of%20hepatitis%20B%20recurrence%20after%20liver%20transplantation%20using%20lamivudine%20or%20lamivudine%20combined%20with%20hepatitis%20B%20Immunoglobulin%20prophylaxis&rft.jtitle=Liver%20transplantation&rft.au=Zheng,%20Shusen&rft.date=2006-02&rft.volume=12&rft.issue=2&rft.spage=253&rft.epage=258&rft.pages=253-258&rft.issn=1527-6465&rft.eissn=1527-6473&rft_id=info:doi/10.1002/lt.20701&rft_dat=%3Cproquest_cross%3E902330641%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=67638546&rft_id=info:pmid/16447195&rfr_iscdi=true |